From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Surface Transforms – interims, “significantly behind plan” and having to ‘evaluate all available cash options’ AGAIN!

By Steve Moore | Monday 30 September 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Previously writing on specialist automotive brake discs company Surface Transforms (SCE), in July with the shares up towards 2p I concluded ‘latest announcement detail suggests to me that risk is high – and follows I previously noting, with operational non-delivery, after arguing sufficient funding on a fundraising last year, less than six months later it was a further equity raise which it states was ‘needed’. That raised a gross £9.5 million and with it already “cash as at 30 June 2024 was £5.0m” and the amount of shares ‘confetti’ already in issue meaning a market cap of approx. £25 million, still currently avoid/sell’. The shares most recently closed at 1.45p… and now half-year results, and what about a currently crashing below 0.50p share price?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 17:21:51